Next-generation sequencing (NGS), which is rapidly entering clinical use, is one of the most decisive instruments used to prepare personalized treatment plans by examining the molecular profile of cancer.

In her speech at the 10th Turkish Medical Oncology Congress, Prof. Dr. Gülay Özgön stated how the basic biomarkers reported by NGS should be interpreted and underlined the points to be considered by sharing case examples worked in her laboratory.